1. 
|
Battle of GLP-1 delivery technologies / M. Yu [et al.] // Adv. Drug Deliv. Rev. - 2018, DOI 10.1016/j.addr.2018.07.009
. - ISSN 0169-409X
Кл.слова (ненормированные):
Albumin fusion -- Exenatide -- Fatty acid conjugate -- Fc fusion -- GLP-1 receptor agonist -- Half-life -- Peptide delivery -- Pharmacokinetics
Аннотация: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) belong to an important therapeutic class for treatment of type 2 diabetes. Six GLP-1 RAs, each utilizing a unique drug delivery strategy, are now approved by the Food and Drug Administration (FDA) and additional, novel GLP-1 RAs are still under development, making for a crowded marketplace and fierce competition among the manufacturers of these products. As rapid elimination is a major challenge for clinical application of GLP-1 RAs, various half-life extension strategies have been successfully employed including sequential modification, attachment of fatty-acid to peptide, fusion with human serum albumin, fusion with the fragment crystallizable (Fc) region of a monoclonal antibody, sustained drug delivery systems, and PEGylation. In this review, we discuss the scientific rationale of the various half-life extension strategies used for GLP-1 RA development. By analyzing and comparing different approved GLP-1 RAs and those in development, we focus on assessing how half-life extending strategies impact the pharmacokinetics, pharmacodynamics, safety, patient usability and ultimately, the commercial success of GLP-1 RA products. We also anticipate future GLP-1 RA development trends. Since similar drug delivery strategies are also applied for developing other therapeutic peptides, we expect this case study of GLP-1 RAs will provide generalizable concepts for the rational design of therapeutic peptides products with extended duration of action. © 2018 Elsevier B.V.
Scopus,
Смотреть статью,
WOS
Держатели документа:
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, 428 Church St, Ann Arbor, MI, United States
Amneal Pharmaceuticals, 50 Horseblock Rd, Brookhaven, NY, United States
Siberian Federal University, 79 Svobodnuy Ave, Krasnoyarsk, Russian Federation
Institute of Biophysics SBRAS, 50 Akademgorodok, Russian Federation
Biointerfaces Institute, NCRC, 2800 Plymouth Rd, Ann Arbor, MI, United States
Department of Biomedical Engineering, 2200 Bonisteel Blvd, Ann Arbor, MI, United States
Доп.точки доступа:
Yu, M.; Benjamin, M. M.; Srinivasan, S.; Morin, E. E.; Shishatskaya, E. I.; Schwendeman, S. P.; Schwendeman, A.
Найти похожие
|
Главная
Каталог книг и продолжающихся изданий библиотеки Института биофизики СО РАН
Стандартный
Библиотека института физики